In vitro immunization of human B lymphocytes with cultured melanoma cells (SK-MEL 28).
Human peripheral blood lymphocytes (PBL) from 10 healthy donors were in vitro immunized using the human melanoma cell line SK-MEL 28 as an immunogen. The parameters necessary to obtain an optimal immune response against the tumor cells in vitro were determined. Different ratios of PBL and SK-MEL 28 were tested during the in vitro immunization period, and their effect on cell viability, specific antibody secretion, and yield of antigen-specific EBV clones was determined. A statistically significant positive dose-response relation was shown to exist between the immunogenic dose present during in vitro immunization and the number of antigen-specific EBV clones that was obtained. A ratio of PBL:SK-MEL 28 cells of 1:1 was found to be optimal and gave 2.6% positive clones from which human monoclonal antibodies specific for the melanoma cells were detected.
Zhang
X M
XM
Department of Biotechnology, University of Lund, Sweden.
Borrebaeck
C A
CA
D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000096:biosynthesis* / Q000276:immunology; D000951:Antigens, Neoplasm; D001402:B-Lymphocytes / Q000276:immunology*; D002459:Cell Fusion; D002461:Cell Line, Transformed; D004306:Dose-Response Relationship, Immunologic; D004854:Herpesvirus 4, Human; D006801:Humans; D007114:Immunization / Q000379:methods*; D008213:Lymphocyte Activation; D008545:Melanoma / Q000276:immunology* / Q000473:pathology; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000276:immunology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins